High-Dose Therapy with Autologous Stem Cells Transplantation in Bing-Neel Syndrome: a retrospective analysis of 14 cases.
Fiche publication
Date publication
mai 2019
Journal
American journal of hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FORNECKER Luc-Matthieu
Tous les auteurs :
Simon L, Lemal R, Fornecker LM, Tournilhac O, Leblond V
Lien Pubmed
Résumé
Bing-Neel syndrome (BNS) is a rare complication in Waldenström macroglobulinemia (WM), defined by a central nervous system involvement with lymphoplasmacytic cells.There is few data regarding the role of ASCT in BNS treatment. In this retrospective, observational, study, we describe fourteen patients with BNS who received ASCT, in five French centres, between 1999 and 2018. In this study, the majority of patients had ASCT in first line (11/14) with good results (only one relapse three years after ASCT), with a median follow-up period of living patients of 35 months after ASCT. ASCT is a good option in fit and eligible patients with BNS, and show long-term responses. This article is protected by copyright. All rights reserved.
Référence
Am. J. Hematol.. 2019 May 31;: